Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has garnered an average rating of “Moderate Buy” from analysts at eighteen research firms, according to a recent report by Marketbeat. This rating reflects a varied outlook, with one analyst recommending a sell, one suggesting a hold, and a substantial sixteen endorsing a buy on the company’s stock.
The average twelve-month price target set by these analysts is approximately $65.76. Recent reports have highlighted significant fluctuations in target prices from various financial institutions. For instance, Bank of America revised its target price for Ultragenyx from $72.00 to $58.00, maintaining a “buy” rating. Similarly, Wells Fargo & Company adjusted its price target from $65.00 to $45.00, rating the stock as “overweight.”
These adjustments come in light of multiple analyst reports. Wedbush reaffirmed a “neutral” rating with a price target of $25.00, while Robert W. Baird lowered its target from $72.00 to $47.00 but maintained an “outperform” rating.
Institutional Investments and Recent Developments
Several hedge funds have altered their positions in Ultragenyx recently. UBS Asset Management, for example, increased its holdings by 14.8% during the first quarter, acquiring an additional 29,984 shares to reach a total of 232,360 shares, valued at approximately $8.41 million. Other significant moves include Envestnet Asset Management, which lifted its position by 6.0%, and Mitsubishi UFJ Asset Management, which boosted its stake by 7.0%.
Currently, institutional investors and hedge funds collectively own 97.67% of Ultragenyx’s stock, indicating strong institutional confidence in the company.
Key recent news has influenced Ultragenyx’s standing. A significant achievement was reported regarding the company’s Phase 3 trial of its AAV8 gene therapy, DTX301, which demonstrated an 18% reduction in ammonia levels compared to a placebo and maintained normal levels over a period of 36 weeks. This positive outcome is critical as it propels the therapy closer to potential regulatory and commercial milestones.
Conversely, some negative sentiment surrounds Ultragenyx due to announcements of securities fraud class action notices. Several law firms are soliciting lead-plaintiff candidates for a class action covering purchases from August 3, 2023December 26, 2025, which could introduce legal risks and pressure the stock in the near term.
Current Stock Performance
On the trading front, Ultragenyx’s stock has seen a slight decline, opening at $21.34 on Tuesday, with a 52-week range between $18.41 and $42.37. The company currently holds a market capitalization of $2.06 billion and reports a price-to-earnings ratio of -3.65, with a beta of 0.16.
In its most recent quarterly earnings report on February 12, 2024, Ultragenyx posted an earnings per share (EPS) of ($1.29), falling short of the consensus estimate of ($1.20) by $0.09. Despite this, revenue for the quarter was $207.28 million, surpassing analyst expectations of $199.60 million. The company’s revenue showed an increase of 25.5% compared to the same quarter last year.
Looking ahead, analysts predict an EPS of -5.18 for the current fiscal year, reflecting ongoing challenges in achieving profitability.
Founded in 2010 and headquartered in Novato, California, Ultragenyx Pharmaceutical focuses on developing therapies for rare and ultra-rare genetic disorders. The company employs a precision medicine approach, utilizing both in-house research and strategic partnerships to advance its product pipeline, which includes treatments like Crysvita, Mepsevii, and Dojolvi.
As Ultragenyx navigates the complexities of the biopharmaceutical landscape, its ability to maintain investor confidence and achieve regulatory milestones will be critical to its future success.
